公开(公告)号：AU2020220205A1

公开(公告)日：2020-09-10

申请号：AU2020220205

申请日：2020-08-21

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  MODY TARAK ,  LOVE RICHARD B ,  BYRD JOHN C ,  CHANG BETTY ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO

IPC: A61K31/505 ,  A61K38/20 ,  A61P35/00

Abstract: TEC FAMILY KINASE INHIBITOR ADJUV ANT THERAPY Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

公开(公告)号：SG10201809111XA

公开(公告)日：2018-11-29

申请号：SG10201809111X

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. Fig. 1

公开(公告)号：PL2526933T3

公开(公告)日：2015-08-31

申请号：PL12166301

申请日：2006-12-28

Applicant: PHARMACYCLICS LLC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING ,  MODY TARAK

IPC: A61K31/00 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

公开(公告)号：NZ736048A

公开(公告)日：2019-09-27

申请号：NZ73604811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK ,  FYFE GWEN ,  BUGGY JOSEPH

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Described is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating relapsed or refractory follicular lymphoma in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：AU2018233032A1

公开(公告)日：2018-10-11

申请号：AU2018233032

申请日：2018-09-21

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  MODY TARAK ,  LOVE RICHARD B ,  BYRD JOHN C ,  CHANG BETTY ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO

IPC: A61K31/505 ,  A61K38/20 ,  A61P35/00

Abstract: TEC FAMILY KINASE INHIBITOR ADJUV ANT THERAPY Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

公开(公告)号：ES2564647T3

公开(公告)日：2016-03-28

申请号：ES12166305

申请日：2006-12-28

Applicant: PHARMACYCLICS LLC

Inventor： HONINGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING ,  MODY TARAK

IPC: A61K31/00 ,  A61K31/519 ,  A61K45/06 ,  A61P35/02 ,  C07D487/04

Abstract: Un inhibidor irreversible de Btk para usar en el tratamiento de la leucemia linfocítica crónica que tiene la fórmula D:**Fórmula** en la que: La es CH2, O, NH o S; Ar es un arilo sustituido o no sustituido o un heteroarilo sustituido o no sustituido; Y es un grupo opcionalmente sustituido seleccionado entre alquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo; Z es C(>=O), OC(>=O), NHC(>=O), C(>=S), S(>=O)x, OS(>=O)x o NHS(>=O)x, donde x es 1 ó 2; R7 y R8 se seleccionan independientemente entre H, alquilo C1-C4 no sustituido, alquilo C1-C4 sustituido, heteroalquilo C1-C4 no sustituido, heteroalquilo C1-C4 sustituido, cicloalquilo C3-C6 no sustituido, cicloalquilo C3-C6 sustituido, heterocicloalquilo C2-C6 no sustituido y heterocicloalquilo C2-C6 sustituido; o R7 y R8 juntos forman un enlace; R6 es H, alquilo C1-C4 sustituido o no sustituido, heteroalquilo C1-C4 sustituido o no sustituido, alcoxialquilo C1-C6, alquilaminoalquilo C1-C8, cicloalquilo C3-C6 sustituido o no sustituido, arilo sustituido o no sustituido, heterocicloalquilo C2-C8 sustituido o no sustituido, heteroarilo sustituido o no sustituido, alquilo (C1-C4) arilo, alquilo (C1-C4) heteroarilo, alquilo (C1-C4) cicloalquilo (C3-C8) o alquilo (C1-C4) heterocicloalquilo (C2-C8) o una sal farmacéuticamente aceptable de los mismos.

公开(公告)号：PE16042015A1

公开(公告)日：2015-11-04

申请号：PE0005922015

申请日：2013-11-01

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  MODY TARAK ,  LOVE RICHARD B ,  BYRD JOHN C ,  CHANG BETTY ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO

IPC: A61K31/505 ,  A61K38/20 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K45/06 ,  A61K2300/00

Abstract: Referida a metodos y composiciones que comprenden un inhibidor de quinasa de la familia TEC covalente para usar en la terapia adyuvante que incluye la terapia adyuvante para el cancer, la vacunacion y el tratamiento de trastornos inmunes e infecciones patogenas

公开(公告)号：CA3113343A1

公开(公告)日：2011-12-08

申请号：CA3113343

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：NZ753024A

公开(公告)日：2020-08-28

申请号：NZ75302411

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Disclosed is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating diffuse large B-cell lymphoma (DLBCL) in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：CY1117587T1

公开(公告)日：2017-03-15

申请号：CY161100196

申请日：2016-03-07

Applicant: PHARMACYCLICS LLC

Inventor： HONINGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING ,  MODY TARAK

IPC: A61K31/00 ,  A61K31/519 ,  A61K45/06 ,  A61P35/02 ,  C07D487/04

Abstract: Αποκαλυπτόμενεςστοπαρόνείναιενώσειςπουσχηματίζουνομοιοπολικούςδεσμούςμεκινάσητυροσίνης Bruton (Btk). Επίσηςπεριγραφόμενηείναιμηαντιστρεπτοίαναστολείς Btk. Μέθοδοιγιατηνπαρασκευήτωνενώσεωναποκαλύπτονται. Επίσηςαποκαλυπτόμενεςείναιφαρμακευτικέςσυνθέσειςπουπεριλαμβάνουντιςενώσεις. Αποκαλύπτονταιμέθοδοιχρήσηςτωναναστολέων Btk, μόνωνή σεσυνδυασμόμεάλλουςθεραπευτικούςπαράγοντες, γιατηθεραπείαχρόνιαςλεμφοκυτταρικήςλευχαιμίας.